Literature DB >> 33783849

The enigma of persistent symptoms in hypothyroid patients treated with levothyroxine: A narrative review.

Petros Perros1, Christina Van Der Feltz-Cornelis2, Enrico Papini3, Endre V Nagy4, Anthony P Weetman5, Laszlo Hegedüs6.   

Abstract

A significant minority of patients with hypothyroidism report persistent symptoms despite achieving normal thyroid biochemistry after levothyroxine (L-T4) replacement. Four principal lines of thinking, which are not mutually exclusive, may explain this enigma. The 'low tissue liothyronine hypothesis' emphasizes the potential imperfections of L-T4 replacement therapy that may lead to hypothyroidism in some tissues such as the brain, while others (eg hypothalamus) are euthyroid. The 'Somatic Symptom and Related Disorders hypothesis' draws attention to an incidental coexistence of a diagnosis of Somatic Symptom and Related Disorders in patients with treated hypothyroidism. The 'autoimmune neuroinflammation hypothesis' highlights the potential consequences of inflammatory mediators due to thyroid autoimmunity (the commonest cause of hypothyroidism) on the brain. The 'comorbidities and psychosocial hypothesis' implicates a variety of physical and psychosocial factors that have been noted to be associated with a diagnosis of hypothyroidism, which may be primarily the cause of persistent complaints. Over the past twenty years, a great deal of time and effort has been expended pursuing the 'low tissue liothyronine hypothesis', which has failed to yield results that translate to patient benefits. This has skewed the balance in clinical practice, in favour of pursuing answers relating to L-T4 and liothyronine combination treatment, while the alternative explanations have been downplayed and potentially useful interventions have been given insufficient attention.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  hypothyroidism; liothyronine; quality of life; thyroxine

Year:  2021        PMID: 33783849     DOI: 10.1111/cen.14473

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  7 in total

1.  Optimal Thyroid Hormone Replacement.

Authors:  Jacqueline Jonklaas
Journal:  Endocr Rev       Date:  2022-03-09       Impact factor: 25.261

2.  Use of thyroid hormones in hypothyroid and euthyroid patients: a 2020 THESIS questionnaire survey of members of the Czech Society of Endocrinology.

Authors:  Jan Jiskra; Jan Paleček; Roberto Attanasio; Laszlo Hegedüs; Endre V Nagy; Enrico Papini; Petros Perros; Roberto Negro; Michal Kršek
Journal:  BMC Endocr Disord       Date:  2022-05-03       Impact factor: 3.263

3.  Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: A 2020 THESIS Questionnaire Survey of Members of the Swedish Endocrine Society.

Authors:  Tereza Planck; Mikael Lantz; Petros Perros; Enrico Papini; Roberto Attanasio; Endre V Nagy; Laszlo Hegedüs
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-06       Impact factor: 5.555

4.  Use of thyroid hormones in hypothyroid and euthyroid patients: a THESIS* survey of Belgian specialists *THESIS: treatment of hypothyroidism in Europe by specialists: an international survey.

Authors:  Maria-Cristina Burlacu; Roberto Attanasio; Laszlo Hegedüs; Endre V Nagy; Enrico Papini; Petros Perros; Kiswendsida Sawadogo; Marie Bex; Bernard Corvilain; Chantal Daumerie; Brigitte Decallonne; Damien Gruson; Bruno Lapauw; Rodrigo Moreno Reyes; Patrick Petrossians; Kris Poppe; Annick Van den Bruel; David Unuane
Journal:  Thyroid Res       Date:  2022-03-05

Review 5.  Enhanced Well-Being Associated with Thyrotoxicosis: A Neglected Effect of Thyroid Hormones?

Authors:  Petros Perros; Laszlo Hegedus
Journal:  Int J Endocrinol Metab       Date:  2022-05-29

6.  Practical Guidelines for Diagnosing and Treating Thyroid Disease Based on the WOMED Metabolic Model of Disease Focusing on Glycolysis and Coenzyme Q10 Deficiency-A Clinical Alternative to the 2021 Retired Clinical Practice Guidelines of the Endocrine Society.

Authors:  Roy Moncayo; Helga Moncayo
Journal:  Diagnostics (Basel)       Date:  2022-01-04

7.  T4+T3 Combination Therapy: An Unsolved Problem of Increasing Magnitude and Complexity.

Authors:  Wilmar M Wiersinga
Journal:  Endocrinol Metab (Seoul)       Date:  2021-09-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.